5x
Up to five times higher uptake
20+
Drugs tested on our platform
0 L
Organic solvent used
2037
Patent protection
OUR PIPELINE
We choose our products where both science and market make sense. Each candidate is selected through a smart, data-driven process, so that we invest only where an improvement truly matters.
We are not a service company. We develop improved versions of medicines that are already approved, using the formulation properties of our porous algae cellulose to enhance drug exposure and performance.
Our products are developed with partners, patients and the planet in mind.
TECHNOLOGY
Drug kept amorphous
-
The drug stays in a fast-dissolving form inside the cellulose pores
-
Up to 50% drug loading
-
Up to 5x uptake, so a lower dose works
-
Validated in vivo, with high exposure
-
3 kg of pure cellulose powder produced
Standard tablet production
-
Direct compression, with no solvents or spray drying
-
The cellulose works as both carrier and binder
-
Fast dissolution and good tablet hardness
Better medicine, smaller footprint
-
Cultivated algae instead of petroleum-based polymers
-
No organic solvents, spray drying or melt extrusion
-
Lower doses mean less drug to make, ship and excrete
-
Pure, biodegradable cellulose
CASE STUDIES
Partner with us
Have a compound that is hard to dissolve? We run paid feasibility studies on partner molecules, and our products can be licensed at every stage of development. Leave your email and we will be in touch.
Team
A lean team with a proven track record
Our team combines drug development, formulation and business experience from Medivir, Orexo, Xspray Pharma and Uppsala University. We work with expert consultants in clinical development, quality, regulatory affairs and business development, and are supported by Uppsala University’s innovation system.
Stina Lundgren
CEO
Jens Landström
CSO
Daniel Bergström
Chairman of the Board
Albert Mihranyan
Founder and Board of Directors
Åsa Wallin
Member of the Board
Mats Johnson, BD
Member of the Board
Allan Asp
Member of the Board
Our
Story
Better medicines, since 2018
Veltio is named after the Greek word βελτίο, meaning “better”. The idea was born from a simple but powerful insight: a natural, renewable material like porous cellulose could make poorly soluble drugs work better.
Our founder Albert Mihranyan, Professor of Pharmaceutical Technology at Uppsala University, spent two decades developing the science behind our algae cellulose. He is the author of more than 90 peer-reviewed papers and the inventor of ten patent families.
Today Veltio is an Uppsala University spin-out with its lab at BMC in Uppsala, and a team focused on taking our own improved medicines to patients.
NEWS
Veltio Pharma AB has been awarded the Bona Postulata award 2026!
The award is given to companies with strong growth potential, and we are honored to be recognized alongside eight other outstanding companies based in Uppsala.
For us, this is an acknowledgment of our dedication to improve pharmaceutical formulations through innovative and sustainable technology.
Click here to see the full article.
Published 29th of April 2026
NEWS
Frequently asked questions
SUPPORTED BY
CONTACT
Contact Us
Post & Email
c/o Folkesson
Dragarbrunnsgatan 78B
Box 3035
750 03 Uppsala
Sweden
Delivery and visits:
BMC
Husargatan 3
752 56 Uppsala